NRC HEALTH - Common Stock, $.001 par value (NRC)

CUSIP: 637372202

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / Common Stock, $.001 par value
Total 13F shares
10,745,800
Total 13F value
$201,606,565
Holder snapshot 6 signals
Share change
-347,025
SEC-reported price per share
$18.77
Number of holders
116
Value change
-$5,605,734
Number of buys
38
Number of sells
78
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
22,550,621

Security key

637372202

Report period

Q4 2025

Institutions

116

Top holders

10

NRC full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 NRC HEALTH SEC filings NRC HEALTH company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of NRC - NRC HEALTH - Common Stock, $.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
KAYNE ANDERSON RUDNICK IN...
Disclosed value leader
KAYNE ANDERSON RUDNICK IN...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G 13F 3/4/5 Lead comparable stake: 12% 13D/G row: KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Showing 1-6 of 15 holder rows.

Quick read

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC's linked filing trail.
Comparable ownership Top 5
KAYNE ANDERSON RUDNICK INVESTMENT... 12%
BlackRock, Inc. 4.4%
Trent S. Green 2.2%
Helen Hrdy 0.62%
Patrick E. Beans 0.16%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
13D/G 13F
Company
13D/G 13F
12%
$47,920,711
2,657,832 shares
 -$5,521,669 31 Dec 2025
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
4.4%
from 13D/G
$13,612,170
1,065,115 shares
 — 30 Sep 2025
Trent S. Green
3/4/5
Chief Executive Officer, Director
3/4/5
2.2%
$6,495,000
500,000 shares
 — 01 Jun 2025
Helen Hrdy
3/4/5
EVP & Chief Operating Officer
3/4/5
0.62%
$2,478,737
140,518 shares
 — 15 Dec 2025
Patrick E. Beans
3/4/5
10%+ Owner
3/4/5
0.16%
$475,673
35,003 shares
 — 12 May 2025
Jordan Nicole Freeman
3/4/5
Chief Accounting Officer
3/4/5
0%
$9,999
771 shares
 +$10,000 31 Jul 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
116
Shares
10,745,800
Rows available
116
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
116
Q4 2025 holders
116
Holder diff
0
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .